Patents
Literature
9 results about "Human respiratory virus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Page issues. Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood.
Sheep colostrum and polypeptide and preparation method thereof
The invention provides a polypeptide, and the sequence of the polypeptide is AEDVGDVAFVKNDT. The polypeptide provided by the invention can inhibit the human respiratory syncytial virus surface protein F so as to inhibit the fusion of the human respiratory syncytial virus surface protein F and a host cell membrane. The invention also provides the sheep colostrum. The sheep colostrum comprises the polypeptide with the antiviral function, so that the sheep colostrum is helpful for old people with relatively weak resistance to resist infection of human respiratory syncytial viruses and promotes repair of respiratory mucosa. The invention also provides a preparation method of the sheep colostrum. The preparation method is simple and can be used for industrial production. The invention also provides a preparation method of the polypeptide.
Owner:HUNAN NUTRITION TREE BIOTECHNOLOGY CO LTD
Antiviral heterocyclic compounds
ActiveUS12612412B2Organic chemistryPharmaceutical active ingredientsPharmacy medicineHuman respiratory virus
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Antiviral heterocyclic compounds
Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which inhibit human respiratory syncytial virus (HRSV) or human metapneumovirus (HMPV). The present invention further relates to pharmaceutical compositions comprising the above-mentioned compounds for administration to a subject suffering from HRSV or HMPV infection. The present invention also relates to methods of treating a subject for HRSV or HMPV infection by administering a pharmaceutical composition comprising a compound of the present invention.
Owner:ENANTA PHARM INC
Inhibitors of human respiratory syncytial virus and metapneumovirus
Owner:MERCK SHARP & DOHME LLC
Inhibitors of human respiratory syncytial virus and metapneumovirus
Owner:MERCK SHARP & DOHME LLC
Antiviral heterocyclic compounds
The present invention relates to formula (I): [Formula 1] JPEG2026513827000477.jpg3557 The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof that (I) inhibit inhibitors of human respiratory syncytial virus (HRSV) or human metapneumovirus (HMPV). The present invention further relates to a pharmaceutical composition comprising the above-mentioned compounds for administration to a subject suffering from HRSV or HMPV infection. The present invention also relates to a method for treating HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Set of primers, composition of the reaction mixture and method for detecting human respiratory syncytial virus types a and b (rsva and rsvb)
The first subject of the invention is a set of primers for amplifying the nucleotide sequence of the RSVA N gene. The second subject of the invention is a set of primers for amplifying the nucleotide sequence of the RSVB N gene. The third subject of the invention is a method for detecting RSVA and RSVB. Another subject of the invention is a method for detecting an infection caused by RSVA or RSVB. The fifth subject of the invention is a kit for detecting an infection caused by RSVA or RSVB.
Owner:GENOMTEC SA
Construction method of a human respiratory syncytial virus newborn mouse infection model and application thereof
The embodiment of the application discloses a method for constructing a human respiratory syncytial virus newborn mouse infection model and application thereof.The method comprises the following steps: inoculating a virus liquid containing a human respiratory syncytial virus (RSV) into a 3-day-old SPF healthy BALB / c newborn mouse through nasal drops, and obtaining the human respiratory syncytial virus newborn mouse infection model after 4-5 days.The application successfully establishes a newborn mouse infection model which is simple to operate, good in repeatability and closer to clinical pathological characteristics.The model has the advantages of high virus infection rate, high similarity of pathological characteristics to human newborn infection, simple model construction method, short cycle, low cost, good stability and strong repeatability, and has a wide application prospect in RSV related research and development.
Owner:ANJI CHANGBAI TECHNOLOGY CO LTD
Pyridine substituted antiviral heterocyclic compound and pharmaceutical composition thereof
The present invention discloses compound of Formula (I), and ester, or prodrug thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV). The present invention further relates to pharmaceutical composition comprising the aforementioned compound for administration to a subject suffering from HRSV or HMPV infection.
Owner:ENANTA PHARM INC